Where does Newave Pharmaceutical Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Newave Pharmaceutical Inc. ranks #17,938 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Newave Pharmaceutical Inc. hold?

Newave Pharmaceutical Inc. holds 16 US utility patents granted between 2019 and 2025, spanning 5 technology areas.

What is Newave Pharmaceutical Inc.'s Innovation Score?

Newave Pharmaceutical Inc. has an Innovation Score of 36.4 out of 100 (top 47% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Newave Pharmaceutical Inc. focus on?

Newave Pharmaceutical Inc.'s top technology area is C07D (Heterocyclic Compounds) with 16 patents, ranking #537 of 3,165 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is Newave Pharmaceutical Inc.'s patent grant rate increasing or decreasing?

Newave Pharmaceutical Inc.'s recent grant velocity is +33% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Newave Pharmaceutical Inc.'s patents?

Newave Pharmaceutical Inc.'s patents average 16.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Newave Pharmaceutical Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Newave Pharmaceutical Inc.

USPTO PatentsView assignee record - 16 granted patents across 5 technology areas, recorded in grant years 2019–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Newave ranks #17,938 of 49,997 tracked US assignees by granted-patent volume, with 16 patents across 5 technology areas.

#17,938
of 49,997 US assignees by volume: Top 47%
by Innovation Score (36.4/100): 16.3
avg claims per patent: +33%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R17938 · US Corporation #17,938 · 16 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-UP · BOOK-FULL

GRANTS-MICRO 16 grants
MID-PACK #17,938/49,997
PHOTO-FINISH Nectar
CPC-NARROW C07D · 5 areas
INNOV-THIN 36.4/100
CLAIMS-RICH 16.3 claims/avg
TYPE-USCORP US Corporation
VEL-UP +33% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Nectar, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Newave’s 36.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.8 pts (27%) Velocity 8.9 pts (24%) Breadth 7.9 pts (22%) Claim depth 9.8 pts (27%)

Qualcomm Incorporated · highest

85
Newave Pharmaceutical · this assignee

36
3D Lighting… · lowest

7

What this shows Newave's Innovation Score is 36.4/100 (top 47% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Newave?

Each dot is one of Newave’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Newave’s own 16.3 claims/patent is ABOVE the 13.9 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Newave vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Newave's grants concentrate

Newave Pharmaceutical Inc. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2019 (6 grants) versus a trough of 1 in 2023. By volume, Newave sits between Nectar, Inc. and Ningbo Utec Electric Co. Ltd..

Newave's three-year grant acceleration

Newave Pharmaceutical Inc. shows 8 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Nectar

16
Neozyme Internati…

16
Neurolens

16
New Mexico Tech U…

16
Newco Enterprises

16
Nexark

16
Ningbo Rotor Elec…

16
Ningbo Utec Elect…

16
Newave Pharmaceut… ◀

16

What this shows Newave holds 16 patents at rank #17,949, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Newave

By rank, the assignees closest to #17,949 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Newave's primary technology class.

Newave's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

36 Top 47% higher than 53% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

Newave Pharmaceutical Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	6	37.5%
2022	4	25.0%
2023	1	6.3%
2024	3	18.8%
2025partial year	2	12.5%

Which technologies does Newave Pharmaceutical Inc. patent most?

C07D - Heterocyclic Compounds 16

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 13

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 9

G06K - Graphical Data Reading ; Presentation OF DATA; Record CARRIERS; Handling Record Carriers 2

G06Q - Information AND Communication Technology [ICT] Specially Adapted FOR Administrative, Commercial, Financial, Managerial OR Supervisory PURPOSES; Systems OR Methods Specially Adapted FOR Administrative, Commercial, Financial, Managerial OR Supervisory Purposes, NOT Otherwise Provided FOR 2

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Newave Pharmaceutical Inc.'s patent record in context - here's where to go next.

Newave Pharmaceutical Inc.'s lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #17,938 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Newave Pharmaceutical Inc. against Nectar, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 36.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.